New York State Common Retirement Fund Has $4.41 Million Position in Castle Biosciences, Inc. $CSTL

New York State Common Retirement Fund raised its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 32.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 215,830 shares of the company’s stock after purchasing an additional 52,671 shares during the period. New York State Common Retirement Fund’s holdings in Castle Biosciences were worth $4,407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of CSTL. Nuveen LLC bought a new stake in shares of Castle Biosciences in the first quarter valued at about $13,450,000. Park West Asset Management LLC bought a new stake in Castle Biosciences in the 1st quarter valued at about $11,141,000. Braidwell LP bought a new stake in Castle Biosciences in the 1st quarter valued at about $7,312,000. Acadian Asset Management LLC grew its position in shares of Castle Biosciences by 65.4% during the 1st quarter. Acadian Asset Management LLC now owns 676,066 shares of the company’s stock worth $13,527,000 after purchasing an additional 267,416 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Castle Biosciences by 11.7% during the first quarter. Vanguard Group Inc. now owns 2,047,565 shares of the company’s stock worth $40,992,000 after purchasing an additional 215,030 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

NASDAQ:CSTL opened at $38.64 on Friday. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $40.61. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $29.66 and its 200 day simple moving average is $23.07. The firm has a market capitalization of $1.13 billion, a PE ratio of -85.87 and a beta of 1.14.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million during the quarter, compared to analysts’ expectations of $71.06 million. On average, analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CSTL has been the topic of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, September 9th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. Robert W. Baird boosted their price target on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, BTIG Research raised their target price on shares of Castle Biosciences from $32.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.43.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 6,695 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.44, for a total value of $203,795.80. Following the sale, the insider owned 56,293 shares in the company, valued at $1,713,558.92. This trade represents a 10.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Tobin W. Juvenal sold 4,693 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $35.58, for a total transaction of $166,976.94. Following the sale, the insider directly owned 84,595 shares in the company, valued at approximately $3,009,890.10. The trade was a 5.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 34,537 shares of company stock valued at $1,037,845 in the last quarter. Insiders own 6.50% of the company’s stock.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.